IMENE HADJI MD

[OncoDaily IO @OncoDailyIO]

The Immune Checkpoint Inhibitors Journey From Early Promise to Lasting Impact - Imène Hadji

@JIPOEditors

https://t.co/GRks2XPjr9

[JIPO Editors @JIPOEditors]

FDA approves Tukysa (tucatinib) + trastuzumab + pertuzumab as maintenance for unresectable or metastatic HER2+ breast cancer. HER2CLIMB-05: median PFS 24.9 vs 16.3 mo (HR 0.64). Boxed warning: hepatotoxicity. https://t.co/ET8ePgQqpO @FDAOncology #JIPO #ION #IHCI @InnoJournals @Innovativehci @ASCO @JCO_ASCO @pfizer

[JIPO Editors @JIPOEditors]

Beyond oncology: Hajjar et al.’s JIPO article proposes a four-quadrant framework for stratifying patients by predicted treatment benefit and toxicity risk—a foundation for developing a clinical decision tool. https://t.co/ndQdBvXDBI @AniaingMD #JIPO #ION #IHCI

[IMENE HADJI MD @IMENEHADJI1]

@JIPOEditors @arjazieh @ANaingMD @OncologyNetwork @oncodaily @OncoDailyIO @InnoScholars

[IMENE HADJI MD @IMENEHADJI1]

Earn 1.0 AMA PRA Category 1 Credit reading JIPO’s flagship review on immune checkpoint inhibitors (Hajjar et al.). Free with an InnoScholar Explorer membership; available until 9/29/2027. https://t.co/31qqdiYZa5 #JIPO #ION #IHCI #CME

[Innovative Oncology Network @OncologyNetwork]

Consider submitting articles in this important topic
#CancerResearch
#oncology